Table 1.

ORs and 95% CIs for lung cancer risk associated with HPV16, HPV18, and HPV16 and/or HPV18 antibodies stratified and adjusted by smoking status in a population-based cohort of fertile-aged women in Finland

HPV seropositiveNo. (%) of positiveOR (95% CI)*
Cases (n = 311)Controls (n = 930)
Nonsmokers
    HPV1619 (17)166 (24)0.81 (0.60-1.15)
    HPV1810 (9)77 (11)1.00 (0.60-1.50)
    HPV16 and/or HPV1822 (20)185 (27)0.80 (0.60-1.06)
Smokers
    HPV1639 (24)26 (17)1.10 (0.90-1.36)
    HPV1814 (9)19 (13)0.80 (0.50-1.14)
    HPV16 and/or HPV1842 (26)33 (22)1.04 (0.80-1.25)
Total*
    HPV1661 (22)194 (23)1.02 (0.87-1.20)
    HPV1824 (9)96 (11)0.90 (0.71-1.11)
    HPV16 and/or HPV1867 (24)220 (26)0.96 (0.83-1.11)
  • *ORs calculated were adjusted for smoking.

  • A nonsmoker was defined by cotinine levels of <20 ng/mL, a smoker by cotinine levels of ≥20 ng/mL.